@ARTICLE{
author={Goel Shom,Tan Antoinette R,Rugo Hope S,Aftimos Philippe,Andric Zoran G,Beelen Andrew Paul,Zhang Jingshan,Yi John S,Malik Rajesh K,O'Shaughnessy Joyce},
year={2022},
title={Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2},
journal={FUTURE ONCOLOGY},
volume={18},
number={33},
pages={3701-3711},
document_type={Article},
} 

@ARTICLE{
author={Tan Antoinette R,...,Popovic Lazar S,...,Milenkovic Dusan M,...,(broj koautora 17)},
year={2022},
title={Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study},
journal={CLINICAL CANCER RESEARCH},
volume={28},
number={4},
pages={629-636},
document_type={Article},
} 

@ARTICLE{
author={Goel Shom,O'Shaughnessy Joyce,Tan Antoinette R,Milev-Krastev Boris,Rugo Hope S,Aftimos Philippe Georges,Yardley Denise A,Andric Zoran G,Wolfgang Curt Douglas,Sorrentino Jessica,Tao Wenli,Beelen Andrew Paul,Malik Rajesh K,Jain Sarika},
year={2021},
title={Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={39},
number={15},
pages={-},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Tan Antoinette R,...,Popovic Lazar S,...,Milenkovic Dusan M,...,(broj koautora 17)},
year={2019},
title={Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial},
journal={LANCET ONCOLOGY},
volume={20},
number={11},
pages={1587-1601},
document_type={Article},
}